Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16834751rdf:typepubmed:Citationlld:pubmed
pubmed-article:16834751lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C0019069lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C0035648lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C1704822lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C0017337lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C0026882lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C1366370lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C0547040lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C0205081lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C0015295lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C2732002lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C1527148lld:lifeskim
pubmed-article:16834751lifeskim:mentionsumls-concept:C0243077lld:lifeskim
pubmed-article:16834751pubmed:issue4lld:pubmed
pubmed-article:16834751pubmed:dateCreated2006-7-12lld:pubmed
pubmed-article:16834751pubmed:abstractTextWe report the case of a patient with mild haemophilia A, due to a Tyr2105Cys mutation in exon 22 of the C1 domain, who developed a high-titre factor VIII inhibitor (maximum titre 1600 BU) with recurrent severe haemorrhages and fatal intracranial bleeding. Based on published data, it appears that although this mutation occurs rarely in patients with mild or moderate haemophilia A, it is frequently associated with the development of high-titre inhibitors.lld:pubmed
pubmed-article:16834751pubmed:languageenglld:pubmed
pubmed-article:16834751pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16834751pubmed:citationSubsetIMlld:pubmed
pubmed-article:16834751pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16834751pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16834751pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16834751pubmed:statusMEDLINElld:pubmed
pubmed-article:16834751pubmed:monthJullld:pubmed
pubmed-article:16834751pubmed:issn1351-8216lld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:PoliGGlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:LippeCClld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:GandiniGGlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:BerntorpEElld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:MorfiniMMlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:FranchiniMMlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:GiuffridaAAlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:OlivieriOOlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:GirelliDDlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:CastamanGGlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:TagarielloGGlld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:de...lld:pubmed
pubmed-article:16834751pubmed:authorpubmed-author:SalvagnoG LGLlld:pubmed
pubmed-article:16834751pubmed:issnTypePrintlld:pubmed
pubmed-article:16834751pubmed:volume12lld:pubmed
pubmed-article:16834751pubmed:ownerNLMlld:pubmed
pubmed-article:16834751pubmed:authorsCompleteYlld:pubmed
pubmed-article:16834751pubmed:pagination448-51lld:pubmed
pubmed-article:16834751pubmed:dateRevised2009-10-21lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:meshHeadingpubmed-meshheading:16834751...lld:pubmed
pubmed-article:16834751pubmed:year2006lld:pubmed
pubmed-article:16834751pubmed:articleTitleTyr2105Cys mutation in exon 22 of FVIII gene is a risk factor for the development of inhibitors in patients with mild/moderate haemophilia A.lld:pubmed
pubmed-article:16834751pubmed:affiliationServizio di Immunoematologia e Trasfusione-Centro Emofilia, Azienda Ospedaliera di Verona, Verona, Italy. massimo.franchini@azosp.vr.itlld:pubmed
pubmed-article:16834751pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16834751pubmed:publicationTypeCase Reportslld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16834751lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:16834751lld:pubmed